When researchers combined clinical features with BRAF mutant allele fraction, patients could be divided into 3 risk groups that were significantly associated with survival.
The results suggest a link, but more research is needed.
Nab-paclitaxel was associated with an improvement in long-term overall survival.
The results led to another approved indication for pembrolizumab.
The association was observed with colon cancer but not rectal cancer.